Cover image of the article: Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran

Image Credit:Nephro-Urol Mon

Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran

Authors

Hamidreza Karimi-Sari1, 2, 3, Seyed Moayed AlavianSeyed Moayed Alavian ORCID2, 3,*
How to Cite:Karimi-Sari H, Alavian SM. Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran. Nephro-Urol Mon. 2017;9(6):e59941. doi: https://doi.org/10.5812/numonthly.59941

Dear Editor,
Recently world health organization (WHO) announced a global program to eliminate Hepatitis C virus (HCV) in the era of new direct acting antiviral drugs (DAAs) by 2030 (1). Finding and curing infected patients seems to be the most important step to reach the goal of HCV elimination (2). Iran has been categorized as a low endemicity country and prevalence of HCV infection is less than 0.5% in the general population (3). Of the 162 chronic hemodialysis patients (CHD), 11 patients (6.8%) had HCV infection in a study by Makhlough et al., which has been published recently in your journal (4). The prevalence of HCV infection was 10 times more than the general population of Iran in patients with CHD of Makhlough et al. study. Since mass-screening of the general population for HCV infection is not cost-effective, screening people with higher risk of HCV infection should be considered as a priority. Thus patients undergoing CHD seem to be a special group for HCV elimination in Iran.
Recent studies also showed that new DAAs are well-tolerated in CHD patients with sustained virological response (SVR) rate of up to 100% (5, 6). Today, accurate and low-cost generic DAAs are generally available in Iran (7). Also treating HCV infection is strongly recommended before kidney transplantation to increase the patients’ survival (8). Infection with HCV was associated with all-cause mortality in a large cohort of patients with CHD (9).
The study of Makhlough et al. also showed that HCV-Antibody (HCV-Ab) does not have enough accuracy for HCV screening in patients with CHD (4). Hence, real-time polymerase chain reaction (PCR) to find HCV-RNA should be considered for HCV screening in patients with CHD.
Finding and curing HCV infected cases among CHD patients should be considered as a priority to reach the goal of HCV elimination and increase their survival.

Footnotes

  • Authors’ Contribution:Both authors contributed equally in this manuscript.

  • Conflict of Interests:Authors declared no conflict of interests.

  • Funding/Support:There is no financial support.

References

  • 1.
    Lancet T. Towards elimination of viral hepatitis by 2030. Elsevier; 2016.
  • 2.
    Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016;16(4):37089. [PubMed ID: 27275164]. https://doi.org/10.5812/hepatmon.37089.
  • 3.
    Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH. Update on the prevalence of hepatitis c virus infection among iranian general population: A systematic review and meta-analysis. Hepat Mon. 2017;17(2).
  • 4.
    Makhlough A, Mahdavi M, Maleki I, Davoodi L, Mousavi T, Hasani-Mansoor SH, et al. The prevalence of hcv infection in hemodialysis population and compared elisa and pcr methods for detecting of hcv infection. Nephro-Urol Mon. 2017;In press(In press). https://doi.org/10.5812/numonthly.45144.
  • 5.
    Abad S, Vega A, Hernandez E, Merida E, de Sequera P, Albalate M, et al. Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. Am J Nephrol. 2017;45(3):267-72. [PubMed ID: 28166520]. https://doi.org/10.1159/000454819.
  • 6.
    Saab S, A. Jimenez M, N. Bau S, Choi G, Durazo FA, M. El-Kabany M, et al. Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis. J Clin Gastroenterol. 2017;51(2):167-73. [PubMed ID: 27548734]. https://doi.org/10.1097/MCG.0000000000000640.
  • 7.
    Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16(8):40959. [PubMed ID: 27799966]. https://doi.org/10.5812/hepatmon.guideline.
  • 8.
    Einollahi B, Alavian SM. Hepatitis C virus infection and kidney transplantation: a review for clinicians. Iran J Kidney Dis. 2010;4(1):1-8. [PubMed ID: 20081297].
  • 9.
    Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18(5):1584-93. [PubMed ID: 17429053]. https://doi.org/10.1681/ASN.2006070736.

Copyright

Copyright © 2017, Nephro-Urology Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Similar Articles

31
Mar
2008
Hepatitis C in Hemodialysis Centers of Golestan Province, Northeast of Iran (2005)

Hepatitis C in Hemodialysis Centers of Golestan Province, Northeast of Iran (2005)

Ali Jabbari,
Sima Besharat,
Behnaz Khodabakhshi

Jabbari A, Besharat S, Khodabakhshi B. Hepatitis C in Hemodialysis Centers of Golestan Province, Northeast of Iran (2005). Hepat Mon. 2008;8(1):. doi:

13
Oct
2018
Elimination of Hepatitis C Virus Infection Among Hemodialysis Patients Will Be Possible If All Patients Undergo Treatment

Elimination of Hepatitis C Virus Infection Among Hemodialysis Patients Will Be Possible If All Patients Undergo Treatment

Seyed Moayed Alavian

Alavian SM. Elimination of Hepatitis C Virus Infection Among Hemodialysis Patients Will Be Possible If All Patients Undergo Treatment. Int J Infect. 2018;5(4):e69025. doi: https://doi.org/10.5812/iji.69025

28
Jul
2023
Prevalence of Hepatitis C Virus and Its Occult Infection in Hemodialysis Patients

Prevalence of Hepatitis C Virus and Its Occult Infection in Hemodialysis Patients

Mohsen Nakhaie,
Ehsan Taheri,
Javad Charostad,
Nasir Arefinia,
Davood Kalantar-Neyestanaki,
Mohammad Rezaei Zadeh Rukerd
,et al.

Nakhaie M, Taheri E, Charostad J, Arefinia N, Kalantar-Neyestanaki D, et al. Prevalence of Hepatitis C Virus and Its Occult Infection in Hemodialysis Patients. Jundishapur J Microbiol. 2023;16(5):e136504. doi: https://doi.org/10.5812/jjm-136504

19
Dec
2003
Prevalence and  Risk Factors of Hepatitis C infection   in hemodialysis Patients (Kermanshah , 1999 – 2000)

Prevalence and Risk Factors of Hepatitis C infection in hemodialysis Patients (Kermanshah , 1999 – 2000)

B Sabour,
P Boromand,
Y Mehrabi,
M Ghanbari,
H Zarrinfam

Sabour B, Boromand P, Mehrabi Y, Ghanbari M, Zarrinfam H. Prevalence and Risk Factors of Hepatitis C infection in hemodialysis Patients (Kermanshah , 1999 – 2000). J Kermanshah Univ Med Sci. 2003;7(3):e81264. doi:

13
Mar
2013
Controversial Report Regarding Seroprevalence of Hepatitis B and C Viruses Among Hemodialysis Patients In Kerman Province, South-East Iran

Controversial Report Regarding Seroprevalence of Hepatitis B and C Viruses Among Hemodialysis Patients In Kerman Province, South-East Iran

Mojgan Noroozi Karimabad,
Gholamhossein Hassanshahi,
Mohammad Kazemi Arababadi

Noroozi Karimabad M, Hassanshahi G, Arababadi MK. Controversial Report Regarding Seroprevalence of Hepatitis B and C Viruses Among Hemodialysis Patients In Kerman Province, South-East Iran. Hepat Mon. 2013;13(3):e7046. doi: https://doi.org/10.5812/hepatmon.7046

More by these authors

Hamidreza Karimi-SariPubMedScholar
Seyed Moayed AlavianPubMedScholar
Share
Cited by
Metrics
Indexed in